Synedgen Presents New Approach to Prevent Infection at International Science Meeting

Synedgen’s active ingredient disrupts bacterial biofilms.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Synedgen’s wound treatments have been shown in preclinical toxicology studies to be safe and effective wound rinses and gels with excellent activity against MRSA and Acinetobacter biofilms, and may also reduce inflammation and facilitate wound healing.

(PRWEB) September 09, 2012

Synedgen VP of Research, Stacy Townsend PhD, will present research showcasing Synedgen’s unique technology to control wound biofilms and inflammation at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), the world’s premier international conference on antimicrobial agents and infectious diseases in San Francisco on September 11.

The presentation entitled, “Novel Biopolymer Wound Treatment Reduces MRSA Biofilms in a partial Thickness Porcine Wound Model and Modulates the Production of IL-8 in Human Macrophages” highlights recent research demonstrating the ability of Synedgen’s proprietary polysaccharide derivatives (PAAG) to prevent and remove biofilms, reduce inflammation and facilitate a more rapid resolution of wound infections.

Studies examined the efficacy of PAAG against two common drug-resistant bacteria, Methicillin-resistant Staphylococcus aureus (MRSA) biofilms and Acinetobacter baumannii biofilms in vitro and in vivo in a partial thickness porcine wound model.

An estimated 60% of infections treated are due to biofilms, aggregates of bacteria that form strong attachments to tissues and protect the bacteria from standard antibacterial treatments, cause harmful inflammatory responses, and contribute to the development of antibiotic resistance.

MRSA biofilms were reduced by more than 99.9% within 1-hour of treatment with 0.05% PAAG rinse or 1% PAAG gel in vitro compared to untreated biofilms. MRSA biofilms in porcine wounds that were rinsed with 0.1% PAAG rinses were immediately reduced 95.8% compared to untreated. In the same porcine model, a 0.1% PAAG rinse followed by treatment with 1% biopolymer gel resulted in a 96.5% reduction compared to untreated wounds after 24-hours.

Acinetobacter baumannii biofilms showed reductions of greater than 99.9% in wounds treated with PAAG rinse and gel immediately after bacterial infection, similar to Sulfamylon® Cream treatment, an antibacterial agent used topically for burn wounds, compared to untreated wounds. A. baumannii biofilms treated with PAAG rinse and gel for 8 days were reduced 98+/- 0.7% compared to untreated biofilms; Sulfamylon Cream treatment resulted in a 97 +/- 2.8% reduction.

In order to assess interactions with human immune cells, human macrophages were pre-treated with 0.02 % of PAAG rinse for 1 hour then exposed to pro-inflammatory mediators such as MRSA DNA or bacterial cell wall products (LPS). Inflammation (measured by IL-8 production) was reduced 5-fold or 3-fold, respectively.

“Synedgen’s biopolymer wound treatments have been shown in preclinical toxicology studies to be safe and effective wound rinses and gels with excellent activity against MRSA and Acinetobacter biofilms, and may also reduce inflammation and facilitate wound healing,” remarked Townsend.

“These results suggest that PAAG could have a significant therapeutic effect on chronic wound infections that are difficult to treat effectively due to the intractable biofilms. Prevention of biofilm establishment, while controlling inflammation, will also be a tremendous asset in advancing wound care,” noted Synedgen President Shenda Baker.

This research was funded by DARPA (Award number N66001-12-C-4053) and US ARMY MRMC (Grant number W81XWH-05-1-0504).

About Synedgen
Synedgen Inc. is an innovative biopharmaceutical company focused on developing novel therapies and products through its proprietary biomaterials technology platform. Product development is targeted to specifically address unmet needs for therapies to treat inflammation, damage or infection at dermal, pulmonary and gastrointestinal surfaces.

Synedgen’s Corporate Headquarters, Research Laboratories and Manufacturing Facility are in Claremont CA. Additional information can be found at Synedgen’s web site at http://www.synedgen.com.


Contact